Overview

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Status:
Active, not recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.

Phase:

Phase 3

Details

Lead Sponsor:

Aragon Pharmaceuticals, Inc.

Treatments:

Androgens
Ascorbic Acid
Estrogens, Conjugated (USP)
Hormones
Methyltestosterone